Primary Sjögren's Syndrome Clinical Trial
Official title:
Reliability, Validity, and Cross-cultural Adaptation of the Turkish Version of the Profile of Fatigue and Discomfort - Sicca Symptoms Inventory in Sjogren Patients
Primary Sjögren's syndrome (pSS) is a chronic, systemic autoimmune disease characterized by disorders of the lacrimal and salivary glands. The disease can be seen in systemic involvement by affecting any organ. It may result in skin, lung and kidney involvement as well as symptoms such as vasculitis and neuropathy. Patients with PSS often report fatigue as an important symptom to manage. Fatigue, defined as an overwhelming feeling of fatigue, lack of energy, and exhaustion, is associated with poor health and functional impairment. Fatigue is a common symptom of pSS. This symptom is the most important cause of loss of function in patients. It is thought that as a result of fatigue in pSS, decrease in mental health related to physical activity level and quality of life in patients, sleep problems, depression and loss of ability to work. Several mechanisms have been proposed to explain the occurrence of fatigue among sjogren patients, but its underlying physiological basis has not been adequately defined. Therefore, it is a complex, multifaceted and poorly understood symptom. In population-based studies, approximately 20% of healthy adults report experiencing fatigue, and this rate rises to 60%-70% among patients with autoimmune disorders. Fatigue is the most common non-exocrine symptom in pSS, and the prevalence of fatigue disability among patients with pSS has been reported to be approximately 70%.
Status | Not yet recruiting |
Enrollment | 100 |
Est. completion date | December 30, 2022 |
Est. primary completion date | June 15, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion Criteria: - Diagnosed with primary Sjögren's syndrome - Patients between the ages of 18-65 - Being literate Exclusion Criteria: - Having cognitive disorders - Having another rheumatological diseases |
Country | Name | City | State |
---|---|---|---|
Turkey | Gazi University | Çankaya | Ankara |
Lead Sponsor | Collaborator |
---|---|
Gazi University |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | the Profile of Fatigue and Discomfort - Sicca Symptoms Inventory | It is scored between 0-7 on an 8-point Likert scale. The 19-item scale evaluates patients in 8 different dimensions: somatic fatigue, mental fatigue, arthralgia, vascular dysfunction, oral dryness, ocular dryness, cutaneous and vaginal dryness. | 10 minutes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03040583 -
The ASSESS National Multi-center Prospective Cohort
|
||
Completed |
NCT01989819 -
Primary Sjögren Syndrome
|
||
Completed |
NCT02291029 -
Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome
|
Phase 2 | |
Terminated |
NCT02610543 -
UCB Proof of Concept Study in Patients With Primary Sjögren's Syndrome
|
Phase 2 | |
Completed |
NCT04078386 -
A Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Primary Sjögren's Syndrome
|
Phase 2 | |
Recruiting |
NCT05087589 -
Efficacy, Safety and Immunological Evaluation of Tofacitinib in the Treatment of Primary Sjogren's Syndrome
|
Phase 2 | |
Recruiting |
NCT04212572 -
Ultrasound Abnormalities of the Salivary Glands in Primary Sjögren's Syndrome According to the Duration of the Disease
|
||
Completed |
NCT02149420 -
PD of VAY736 in Patients With Primary Sjögren's Syndrome
|
Phase 2 | |
Recruiting |
NCT04858464 -
Reliability, Validity of the Turkish Version of the Primary Sjögren Syndrome Quality of Life (PSS-QoL) Questionnaire
|
||
Recruiting |
NCT03003572 -
Autoreactive Anti-Ro/SSA IgE To Determine Primary SjögRen's Syndrome's Disease Activity
|
||
Completed |
NCT00632866 -
Hydroxychloroquine Versus Placebo in Primary Sjögren's Syndrome
|
Phase 3 | |
Completed |
NCT02334306 -
A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome
|
Phase 2 | |
Completed |
NCT02775916 -
Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome
|
Phase 2 | |
Completed |
NCT02464319 -
A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's Syndrome
|
Phase 2 | |
Terminated |
NCT01552681 -
Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögren's Syndrome
|
Phase 2 | |
Completed |
NCT04186871 -
Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis
|
Phase 2 | |
Completed |
NCT00426543 -
Effect of B-cell Depletion in Patients With Primary Sjögren's Syndrome
|
Phase 2 | |
Recruiting |
NCT04981145 -
The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome
|
Phase 4 | |
Completed |
NCT06432101 -
Acupuncture Combined With Hydroxychloroquine
|
N/A | |
Completed |
NCT03627065 -
A Study of INCB050465 in Primary Sjögren's Syndrome
|
Phase 2 |